Drug profile · INN
CARISOPRODOL
carisoprodol (CARISOPRODOL) is a unknown. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
carisoprodol (CARISOPRODOL) is a unknown. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Unknown
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
WO 2026112397
COMPOSITIONS ET PROCÉDÉS DE PRODUCTION DE VIRUS ADÉNO-ASSOCIÉS
EP 4732903
COKRISTALLE VON PITOLISTANTHYDROCHLORID
WO 2026085433
PROCÉDÉS POUR PRÉPARER DES CONJUGUÉS OLIGONUCLÉOTIDIQUES
WO 2026060131
ADDITIFS POUR LA PRODUCTION DE VECTEURS VIRAUX
WO 2026055127
PROCÉDÉ DE PRODUCTION D'UN MODULATEUR DE RÉCEPTEUR GABA
WO 2025252204
DISPERSIONS SOLIDES AMORPHES D'UN INHIBITEUR DE BRAF
WO 2025232885
PROCÉDÉ DE PRÉPARATION D'UN AGENT DE DÉGRADATION DE LA TYROSINE KINASE DE BRUTON
WO 2025218772
FORMES SOLIDES COMPRENANT UN AGENT DE DÉGRADATION DE TYROSINE KINASE DE BRUTON ET LEURS UTILISATIONS
WO 2025214466
CONJUGUÉS DE PYRROLOBENZODIAZÉPINE CIBLÉS
WO 2025201453
COMPOSÉS MACROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE RAS
US 12427155
Treatment for tau-related diseases
US 12421310
CD47 binding agents
US 12419873
Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases
US 12414999
Compositions and methods relating to macrophages and/or monocytes with adhered particles
US 12396974
Ketone ester as a therapeutic treatment of Covid-19 and related viral infections
WO 2025172541
NOUVELLE COMPOSITION POUR L'AMÉLIORATION DE LA RECONSTITUTION DE LA MOELLE OSSEUSE ET DE LA RÉCUPÉRATION PÉRIPHÉRIQUE DES NUMÉRATIONS DE NEUTROPHILES ET DE PLAQUETTES
WO 2025168072
COMPOSÉS HÉTÉROCYCLIQUES, COMPOSITIONS ASSOCIÉES ET MÉTHODES DE TRAITEMENT ASSOCIÉS
WO 2025168081
TRAITEMENT D'UN TROUBLE PROLIFÉRATIF DES LYMPHOCYTES B AVEC UN COMPOSÉ ACTIVATEUR DE DÉGRADATION CHIMÉRIQUE
WO 2025165930
MÉTHODES DE TRAITEMENT DE L'AMYOTROPHIE SPINALE
US 12377106
Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK
🔒 ★ Optimizing Pharmaceutical Manufacturing: The Critical Role of Dew Point Monitoring
Dew point monitoring is crucial for controlling humidity in sensitive industrial environments where even trace moisture can compromise produ…
A26 Informational Reports: Insights for Pharma Stakeholders
Total grants and donations received by the AMA in 2025 amounted to $3,666,000, supporting various public health initiatives.
Examining the Validity of External Controls Relative to Randomized Controls
This presentation discusses the validity of external controls in medical product development and their comparison to randomized controls.
carisoprodol (CARISOPRODOL) is a unknown. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
CARISOPRODOL is a marketed brand name for carisoprodol. Check FDA Drugs@FDA for the current US label holder and prescribing information.
carisoprodol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.